Loading…
Employees: 32
Size Qurient (115180.KS) is a South Korea Health Care company (Biotechnology) with a market value of $503M, the 331st largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩15,310 on 6 Nov 2026.
Performance Over six months the shares fell 59.0%, against -12.8% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue fell 20.1% over the last twelve months (peer median -3.5%); the operating margin is -516.7% (peer median -3.6%).
Valuation It trades at 98.9× enterprise value to sales against a peer median of 7.0× (3rd most expensive of 16).
Capital Return on invested capital runs 81.8 points below its cost of capital (5.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩7.07B | ₩6.98B | ₩9.18B | ₩9.03B | ₩8.47B |
| Revenue growth | — | -24% | +2% | +7% | — |
| Gross profit | -₩251M | -₩31.4M | ₩496M | ₩944M | ₩1.06B |
| EBITDA | -₩35.5B | -₩28.5B | -₩26.6B | -₩22.4B | -₩26.8B |
| Net income | -₩38.4B | -₩30.1B | -₩23.6B | -₩21.1B | -₩25.5B |
| Free cash flow | -₩31.5B | -₩27.5B | -₩22.1B | n/a | -₩24.2B |
| Capital expenditure | ₩3.65B | ₩3.70B | ₩83.7M | ₩101M | ₩519M |
| Total debt | ₩13.4B | ₩12.7B | ₩841M | ₩334M | ₩807M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 115180.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -36.7% | -11.9% | 2nd lowest of 21 |
| 6-month return | -59.0% | -12.8% | lowest of 20 |
| Distance from 52-week high | -75.7% | -41.5% | lowest of 21 |
| Revenue growth (TTM) | -20.1% | -3.5% | 5th lowest of 15 |
| Operating margin | -516.7% | -3.6% | 4th lowest of 16 |
| EV / Sales | 98.9× | 7.0× | 3rd most expensive of 16 |
| ROIC minus cost of capital | -81.8 pp | -5.8 pp | 2nd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | 28.3× | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | 3.8× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | 13.7× | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 48.0× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 5.2× | 15.2% | +0.5% |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 8.0× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | 8,168.1× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 5.4× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 2.2× | n/a | n/a |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | 4.0× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | 7.0× | 31.6% | +7.0% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | 5.2× | 6.0% | -62.3% |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 2.5× | -14.9% | -36.1% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 18.0× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | 258.1× | n/a | n/a |